{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:20:46Z","timestamp":1792264846398,"version":"4.4.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470213"],"award-info":[{"award-number":["82470213"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["20224Z0002"],"award-info":[{"award-number":["20224Z0002"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jtct.2026.09.035","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:31:23Z","timestamp":1789972283000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Early Prophylactic Rituximab Reduces EBV Infection and PTLD in High-risk patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4225-9923","authenticated-orcid":false,"given":"Ao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoxing","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuohui","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanhe","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengkai","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2719-3805","authenticated-orcid":false,"given":"Xiaoxia","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.jtct.2026.09.035_bib0001","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1016\/j.cell.2022.08.026","article-title":"Epstein-Barr virus: biology and clinical disease","volume":"185","author":"Damania","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.jtct.2026.09.035_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.878953","article-title":"Reinforcement of cell-mediated immunity driven by tumor-associated Epstein-Barr virus (EBV)-specific T cells during targeted B-cell therapy with rituximab","volume":"14","author":"Tischer-Zimmermann","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2026.09.035_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1427637","article-title":"Impact of prophylaxis with rituximab on EBV-related complications after allogeneic hematopoietic cell transplantation in children","volume":"15","author":"Marja\u0144ska","year":"2024","journal-title":"Front Immunol"},{"issue":"19","key":"10.1016\/j.jtct.2026.09.035_bib0004","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1200\/JCO.2015.64.2405","volume":"34","author":"Styczynski","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jtct.2026.09.035_bib0005","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/blood.2020007905","article-title":"CD4+ T-cell reconstitution predicts survival outcomes after acute graft-versus-host-disease: a dual-center validation","volume":"137","author":"de Koning","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2026.09.035_bib0006","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00281-020-00828-7","article-title":"The role of the thymus in allogeneic bone marrow transplantation and the recovery of the peripheral T-cell compartment","volume":"43","author":"Velardi","year":"2021","journal-title":"Semin Immunopathol"},{"issue":"6","key":"10.1016\/j.jtct.2026.09.035_bib0007","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/leu.2011.26","article-title":"Features of Epstein-Barr virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation","volume":"25","author":"Peric","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2026.09.035_bib0008","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1756-8722-6-94","article-title":"Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation","volume":"6","author":"Lin","year":"2013","journal-title":"J Hematol Oncol"},{"issue":"6","key":"10.1016\/j.jtct.2026.09.035_bib0009","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMra1702693","article-title":"Post-transplantation lymphoproliferative disorders in adults","volume":"378","author":"Dierickx","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.09.035_bib0010","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2015.88","article-title":"Post-transplant lymphoproliferative disorders","volume":"2","author":"Dharnidharka","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"10.1016\/j.jtct.2026.09.035_bib0011","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/s41409-025-02542-0","volume":"60","author":"Zhen","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.09.035_bib0012","article-title":"Factors associated with post-transplant active Epstein-Barr virus infection and lymphoproliferative disease in hematopoietic stem cell transplant recipients: a systematic review and meta-analysis","volume":"9","author":"Enok Bonong","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"7","key":"10.1016\/j.jtct.2026.09.035_bib0013","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3324\/haematol.2016.144428","article-title":"Management of Epstein-Barr virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines","volume":"101","author":"Styczynski","year":"2016","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.jtct.2026.09.035_bib0014","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood.V97.5.1165","article-title":"Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients","volume":"97","author":"Stevens","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.09.035_bib0015","series-title":"The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies","first-page":"411","article-title":"Post transplant lymphoproliferative syndromes","author":"Styczynski","year":"2024"},{"issue":"12","key":"10.1016\/j.jtct.2026.09.035_bib0016","doi-asserted-by":"crossref","first-page":"1049.e1","DOI":"10.1016\/j.jtct.2025.08.017","article-title":"Long-term efficacy of Epstein-Barr virus-specific T cells for Epstein-Barr virus-associated post-transplantation lymphoproliferative disorder after allogeneic stem cell transplantation: a real-world study","volume":"31","author":"Sun","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"10.1016\/j.jtct.2026.09.035_bib0017","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1399-3062.2009.00411.x","article-title":"Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases","volume":"11","author":"Styczynski","year":"2009","journal-title":"Transpl Infect Dis"},{"issue":"12","key":"10.1016\/j.jtct.2026.09.035_bib0018","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1111\/tri.14107","article-title":"EBV-specific cytotoxic T lymphocytes for refractory EBV-associated post-transplant lymphoproliferative disorder in solid organ transplant recipients: a systematic review","volume":"34","author":"Liu","year":"2021","journal-title":"Transpl Int"},{"issue":"12","key":"10.1016\/j.jtct.2026.09.035_bib0019","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1182\/bloodadvances.2023011626","article-title":"Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol","volume":"8","author":"Nikiforow","year":"2024","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.jtct.2026.09.035_bib0020","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood.2020005466","article-title":"EBV+ lymphoproliferative diseases: opportunities for leveraging EBV as a therapeutic target","volume":"139","author":"Toner","year":"2022","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.jtct.2026.09.035_bib0021","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242216029","article-title":"Pre-emptive use of rituximab in Epstein-Barr virus reactivation: incidence, predictive factors, monitoring, and outcomes","volume":"24","author":"Papalexandri","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.jtct.2026.09.035_bib0022","first-page":"145","article-title":"Low dose rituximab for pre-emptive treatment of Epstein Barr virus reactivation after allogenic hematopoietic stem cell transplantation","volume":"67","author":"Delapierre","year":"2019","journal-title":"Curr Res Transl Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.09.035_bib0023","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41409-023-02155-5","article-title":"Rituximab for posttransplant lymphoproliferative disorder: therapeutic, preemptive, or prophylactic?","volume":"59","author":"Storek","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2026.09.035_bib0024","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1080\/10428194.2018.1543877","article-title":"Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk","volume":"60","author":"Van Besien","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.jtct.2026.09.035_bib0025","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/bmt.2011.28","article-title":"In vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT","volume":"47","author":"Dominietto","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2026.09.035_bib0026","doi-asserted-by":"crossref","first-page":"132.e1","DOI":"10.1016\/j.jtct.2022.10.023","article-title":"Pre-hematopoietic stem cell transplantation rituximab for Epstein-Barr virus and post-lymphoproliferative disorder prophylaxis in alemtuzumab recipients","volume":"29","author":"Patel","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.09.035_bib0027","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s40164-025-00665-0","article-title":"Epstein-Barr virus infection following allogeneic hematopoietic stem cell transplantation in the era of letermovir for cytomegalovirus prophylaxis","volume":"14","author":"Huang","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.jtct.2026.09.035_bib0028","article-title":"Letermovir prophylaxis guided by cytomegalovirus cell-mediated immunity improves the outcomes of allogeneic hematopoietic stem cell transplant recipients","author":"Wang","year":"2025","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.jtct.2026.09.035_bib0029","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41408-024-01092-w","article-title":"Efficacy of blinatumomab as maintenance therapy for B-lineage acute lymphoblastic leukemia\/lymphoma following allogeneic hematopoietic cell transplantation","volume":"14","author":"Huang","year":"2024","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.jtct.2026.09.035_bib0030","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"27","key":"10.1016\/j.jtct.2026.09.035_bib0031","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.jtct.2026.09.035_bib0032","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/bmt.2008.386","article-title":"Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia","volume":"43","author":"Styczynski","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2026.09.035_bib0033","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/ajh.27750","article-title":"MRD and NK-cell chimerism predict transplant outcomes in allogeneic hematopoietic stem cell transplantation recipients","volume":"100","author":"Chen","year":"2025","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.jtct.2026.09.035_bib0034","doi-asserted-by":"crossref","first-page":"417","DOI":"10.21147\/j.issn.1000-9604.2025.03.10","article-title":"Venetoclax and azacitidine compared with intensive chemotherapy for adverse-risk acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation in first complete remission: a multicenter study of TROPHY group","volume":"37","author":"Wen","year":"2025","journal-title":"Chin J Cancer Res"},{"issue":"2","key":"10.1016\/j.jtct.2026.09.035_bib0035","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/bjh.19958","article-title":"Humanized anti-CD25 monoclonal antibody replaces methotrexate as acute graft-versus-host disease prophylaxis in haploidentical allogeneic haematopoietic stem cell transplantation","volume":"206","author":"Zhang","year":"2025","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.jtct.2026.09.035_bib0036","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/S2352-3026(15)00045-9","article-title":"Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis","volume":"2","author":"Admiraal","year":"2015","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2026.09.035_bib0037","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2025-7803","article-title":"Efficacy of early single low dose of rituximab in prophylaxis of EBV reactivation and EBV related post-transplant lymphoproliferative disorder after allogeneic hematopoietic cell transplantation","volume":"146","author":"Liu","year":"2025","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2026.09.035_bib0038","article-title":"Prophylactic rituximab administered on day-1 during conditioning significantly reduces early EBV reactivation in pediatric allogeneic HSCT: Real-world evidence from a propensity-matched cohort of 834 patients","volume":"146","author":"Zhang","year":"2025","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2026.09.035_bib0039","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41409-025-02742-8","article-title":"Usage of rabbit anti-thymocyte \/anti-T-lymphocyte globulins (ATG \/ ATLG) for hematological malignancies in allogeneic hematopoietic cell transplantation: best practice recommendations from the EBMT Practice Harmonisation and Guidelines Committee","volume":"61","author":"Battipaglia","year":"2026","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2026.09.035_bib0040","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.jcyt.2023.04.003","article-title":"Epstein\u2012Barr virus-associated cellular immunotherapy","volume":"25","author":"Zhang","year":"2023","journal-title":"Cytotherapy"},{"issue":"3","key":"10.1016\/j.jtct.2026.09.035_bib0041","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41409-019-0699-6","article-title":"Pre-emptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: a comparative study for immune recovery and clinical outcomes","volume":"55","author":"Stocker","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2026.09.035_bib0042","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3324\/haematol.2022.281134","article-title":"Rituximab therapy after pediatric hematopoietic stem cell transplantation can cause prolonged B-cell impairment and increases the risk for infections: a retrospective matched cohort study","volume":"108","author":"Launspach","year":"2023","journal-title":"Haematologica"},{"issue":"25","key":"10.1016\/j.jtct.2026.09.035_bib0043","doi-asserted-by":"crossref","first-page":"6145","DOI":"10.1182\/blood-2011-12-395970","article-title":"Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence","volume":"119","author":"Arai","year":"2012","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2026.09.035_bib0044","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1182\/blood-2013-04-495895","article-title":"Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial","volume":"122","author":"Cutler","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.09.035_bib0045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.967026","article-title":"The impact of rituximab administered before transplantation in patients undergoing allogeneic hematopoietic stem cell transplantation: a real-world study","volume":"13","author":"Wei","year":"2022","journal-title":"Front Immunol"},{"issue":"16","key":"10.1016\/j.jtct.2026.09.035_bib0046","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO-25-03104","article-title":"Randomized, placebo-controlled trial of B-cell depletion for prevention of corticosteroid-requiring chronic graft-versus-host disease","volume":"44","author":"Cutler","year":"2026","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2026.09.035_bib0047","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1182\/blood-2025-2504","article-title":"Efficacy of low-dose rituximab as preemptive treatment of EBV-DNA-emia after allogeneic hematopoietic stem cell transplantation","volume":"146","author":"Wang","year":"2025","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2026.09.035_bib0048","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1007\/s40121-023-00841-x","article-title":"Applying rituximab during the conditioning regimen prevents Epstein-Barr virus infection following allogeneic hematopoietic stem cell transplant in a children's cohort: a retrospective case-control study","volume":"12","author":"Ruan","year":"2023","journal-title":"Infect Dis Ther"},{"issue":"5","key":"10.1016\/j.jtct.2026.09.035_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2024.02.025","article-title":"Long-term clinical outcomes and B cell immune reconstitution following Allo-HCT with prophylactic, post-transplant rituximab","volume":"30","author":"Kennedy","year":"2024","journal-title":"Transplant Cell Ther"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726007657?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726007657?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:44:16Z","timestamp":1792097056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726007657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":49,"alternative-id":["S2666636726007657"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.09.035","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early Prophylactic Rituximab Reduces EBV Infection and PTLD in High-risk patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.09.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}